Project Grant F32CA288138
Award Date
12/1/24
Completion Date
7/31/25
Dollars Obligated
$124K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
This Project Grant award of $858,186 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to decipher the mechanisms leading to immune-related myocarditis, a fatal adverse event associated with immune checkpoint inhibitor (ICI) cancer therapies. The research aims to identify novel...
This federal Project Grant award of $636,222 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of Pittsburgh to investigate how immune checkpoint inhibitor-associated gut bacteria can modulate tumor immunity and enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in melanoma. The key goals of the research are to: 1) Determine whether ICI-associated bacteria metabolize dietary tryptophan into aryl...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...
This Project Grant award of $754,511 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Jackson Laboratory to discover host genetic factors that influence response to immune checkpoint inhibitor (ICI) cancer treatments. The project aims to: Expand and refine a mouse experimental platform to map quantitative trait loci (QTLs) associated with ICI response, focusing on defining the genetic mechanisms behind epistatic interactions. Challenge top...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,419,108 to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The award will fund research to gain insights into how blocking the SEMA4D signaling pathway, when combined with immune checkpoint blockade, enhances the activity of antigen-presenting dendritic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $333,504 to The Washington University to conduct research on the role of peritoneal myeloid cells in colorectal cancer peritoneal metastasis and implications for immunotherapy. The award commences on July 1, 2025 and is scheduled for completion by July 31, 2027. The key objectives of this research project are to: Profile immune cell phenotypical changes in the peritoneal fluid and...